Rivaroxaban (Xarelto®) 2.5 mg
Rivaroxaban (Xarelto®) 2.5 mg film-coated tablets are available for reimbursement under the Community Drug Schemes when co-administered with aspirin, for the prevention of atherothrombotic events in adult patients with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events. A Managed Access Protocol is in place for rivaroxaban (Xarelto®) 2.5 mg film-coated tablets. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of rivaroxaban (Xarelto®) 2.5 mg film-coated tablets.
A prescriber must submit an online application for individual reimbursement approval for each patient. GPs and hospital prescribers, once user-registered with the HSE-Primary Care Reimbursement Service (PCRS), can apply for reimbursement of rivaroxaban (Xarelto®) 2.5 mg film-coated tablets. Due to the information that is required to be submitted, the prescriber responsible for the initiation of treatment should complete the online application.
A copy of the HSE-Managed Access Protocol for Rivaroxaban (Xarelto®) 2.5 mg, correspondence issued to prescribers, and Anticoagulation Prescribing Tips, can be found in the related files section below.